Bispecific checkpoint inhibitor antibodies
The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
1. A heterodimeric anti-LAG-3×anti-CTLA-4 antibody comprising:
a) a first monomer having the amino acid sequence of SEQ ID NO: 39138;
b) a second monomer having the amino acid sequence of SEQ ID NO: 39143; and
c) a third monomer having the amino acid sequence of SEQ ID NO: 39153.
2. A nucleic acid composition comprising:
a) a first nucleic acid encoding the first monomer according to claim 1 ;
b) a second nucleic acid encoding the second monomer according to claim 1 ; and
c) a third nucleic acid encoding the third monomer to claim 1 .
3. An expression vector composition comprising:
a) a first expression vector comprising the first nucleic acid of claim 2 ;
b) a second expression vector comprising the second nucleic acid of claim 2 ; and
c) a third expression vector comprising the third nucleic acid of claim 2 .
4. A host cell comprising the expression vector composition of claim 3 .
5. A method of making a heterodimeric antibody comprising culturing a host cell of claim 4 under conditions wherein the heterodimeric antibody is expressed, and recovering the antibody.
6. A heterodimeric anti-LAG-3×anti-CTLA-4 antibody comprising:
a) a first monomer comprising a VH-CH1-hinge-CH2-CH3 monomer having the amino acid sequence of SEQ ID NO: 39138;
b) a second monomer comprising an anti-CTLA-4 scFv-linker-CH2-CH3 monomer having the amino acid sequence of SEQ ID NO: 39143; and
c) a third monomer comprising a VL-CL monomer having the amino acid sequence of SEQ ID NO: 39153, wherein VH is a variable heavy domain, VL is a variable light domain, and VH and VL form a LAG-3 binding domain.